A phase 3 trial of delamanid, a newer oral drug for treating multidrug-resistant tuberculosis (MDR-TB), found no statistically significant reduction in time to sputum culture conversion when compared to placebo, but that it was safe and well tolerated.

Credit: Janice Haney Carr CDC

Read more at CIDRAP

See also:

Jan 7 Lancet Respir Med abstract

Jan 7 Lancet Respir Med audio file

Jan 7 Lancet Respir Med commentary